Literature DB >> 15856460

Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes.

Klaus Jung, Arielle Meisser, Paul Bischof.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15856460     DOI： 10.1002/ijc.21129

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  10 in total

1.  Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens.

Authors:  Kathryn Thrailkill; Gael Cockrell; Pippa Simpson; Cynthia Moreau; John Fowlkes; R Clay Bunn
Journal:  Clin Chem Lab Med       Date:  2006       Impact factor: 3.694

2.  Translating molecular medicine into clinical tools: doomed to fail by neglecting basic preanalytical principles.

Authors:  Klaus Jung; Ferdinando Mannello; Michael Lein
Journal:  J Transl Med       Date:  2009-10-14       Impact factor: 5.531

3.  Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships.

Authors:  N El Houda Agueznay; C Badoual; S Hans; A Gey; B Vingert; S Peyrard; F Quintin-Colonna; P Ravel; P Bruneval; S Roncelin; B Lelongt; J Bertoglio; W H Fridman; D Brasnu; E Tartour
Journal:  Clin Exp Immunol       Date:  2007-08-03       Impact factor: 4.330

4.  Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder.

Authors:  Andrea Staack; Steffen Badendieck; Dietmar Schnorr; Stefan A Loening; Klaus Jung
Journal:  BMC Urol       Date:  2006-08-10       Impact factor: 2.264

5.  Serum Matrix Metalloproteinases and Left Atrial Remodeling-The Hoorn Study.

Authors:  Pauline B C Linssen; Hans-Peter Brunner-La Rocca; Casper G Schalkwijk; Joline W J Beulens; Petra J M Elders; Amber A van der Heijden; Roderick C Slieker; Coen D A Stehouwer; Ronald M A Henry
Journal:  Int J Mol Sci       Date:  2020-07-13       Impact factor: 5.923

6.  Assessing the value of matrix metalloproteinase 9 (MMP9) in improving the appropriateness of referrals for colorectal cancer.

Authors:  S Damery; L Nichols; R Holder; S T Ward; S Warmington; S Wilson; M J Wakelam; J James; T Ismail
Journal:  Br J Cancer       Date:  2013-02-07       Impact factor: 7.640

7.  Is serum matrix metalloproteinase 9 a useful biomarker in detection of colorectal cancer? Considering pre-analytical interference that may influence diagnostic accuracy.

Authors:  K Jung
Journal:  Br J Cancer       Date:  2008-07-22       Impact factor: 7.640

8.  Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma.

Authors:  Javier Cotignola; Boris Reva; Nandita Mitra; Nicole Ishill; Shaokun Chuai; Ami Patel; Shivang Shah; Gretchen Vanderbeek; Daniel Coit; Klaus Busam; Allan Halpern; Alan Houghton; Chris Sander; Marianne Berwick; Irene Orlow
Journal:  BMC Med Genet       Date:  2007-03-08       Impact factor: 2.103

9.  Levels of matrix metalloproteinases differ in plasma and serum - aspects regarding analysis of biological markers in cancer.

Authors:  Andreas Jonsson; Claes Hjalmarsson; Peter Falk; Marie-Lois Ivarsson
Journal:  Br J Cancer       Date:  2016-05-17       Impact factor: 7.640

10.  Serum MMP-3 and its association with central arterial stiffness among young adults is moderated by smoking and BMI.

Authors:  Nathaniel J Iannarelli; Adam J MacNeil; Kylie S Dempster; Terrance J Wade; Deborah D O'Leary
Journal:  Physiol Rep       Date:  2021-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.